stockrow
Saturday 7 November 2026
Export JBIO’s income statement to Excel — free account
Jade Biosciences, Inc.
JBIO Healthcare Biotechnology
- EPS
- +11.6%
- Free cash flow
- −115.1%
Quarter to June 2026, against a year earlier
15.03
0.93
+6.60%
Follow JBIO
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(96.67%) | (85.55%) | (66.98%) | (46.16%) | |
| (85.61%) | (57.84%) | (62.68%) | (42.54%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(70.09%) | (36.76%) | (41.98%) | (33.66%) | |
Free Cash Flow per Share |
(1.95) | (3.03) | (1.73) | (2.02) | |
Free Cash Flow |
(77.14) | (94.95) | (100.01) | (123.51) | |
Capital Expenditures |
(0.29) | (0.26) | — | — | |
| Other line items | |||||
Cash ROIC |
(20.39%) | (14.20%) | (16.46%) | (13.71%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.61 | 0.77 | 0.80 | 0.83 | |
Depreciation/Fixed assets |
(13.32) | (5.76) | (7.91) | (11.08) | |
Capex/Depreciation |
0.12 | 0.27 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.94) | (3.02) | (1.73) | (2.02) | |
Capex per Share |
(0.01) | (0.01) | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | — | — |
Columns are period end dates · fundamentals updated 26 Oct 2026